<DOC>
	<DOCNO>NCT01288664</DOCNO>
	<brief_summary>This pilot study evaluate efficacy safety Tacrolimus Sustained-release Capsules ( ADVAGRAF ) induction therapy Lupus Nephritis ( LN ) ( V , III +V , IV+V ) .</brief_summary>
	<brief_title>Efficacy Safety Tacrolimus Sustained-release Capsules Induction Phase Treatment Lupus Nephritis</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1 . Subjects either sex , 1465 year age ; 2 . Diagnosis systemic lupus erythematosus ( SLE ) accord albumincreatinine ratio ( ACR ) criterion ( 1997 ) ; 3 . Kidney biopsy within 6 month prior study histologic diagnosis ( ISN/RPS 2003 classification LN ) class V , III +V , IV+V ; 4 . LN ( Class IV+V ) : proteinuria &gt; 1g/24hr Scr &gt; 1.3 mg/dl active urinary sediment ( erythrocyte cast , &gt; 5 white blood cell count ( WBC ) /high power field ( hpf ) ( exclude infection ) , &gt; 5 red blood cell count ( RBC ) /hpf ; 5 . LN ( Class V III +V ) : proteinuria &gt; 2g/24hr Scr &gt; 1.3 mg/dl ; 6 . Provision write informed consent subject guardian 1 . Inability unwillingness provide write informed consent 2 . Usage immunosuppression therapy ( MMF , Cyclophosphamide ( CTX ) , Cyclosporine A ( CysA ) , methotrexate ( MTX ) ect ) 1 week within 1 month Pulse intravenous MP treatment prior recruitment 3 . Scr &gt; 4mg/dl ( 354umol/L ) 4 . Needing pulse intravenous Methylprednisolone ( MP ) intravenous immunoglobulin 5 . Lupus encephalopathy 6 . Diagnosed diabetes mellitus ( DM ) ; Malignant tumor ( except fully cure basal cell carcinoma ) 7 . History significant gastrointestinal disorder ( e.g . severe chronic diarrhea active peptic ulcer disease ) within 3 month prior enter study 8 . Any Active systemic infection history serious infection within one month entry 9. know infection HIV , hepatitis B , hepatitis C 10 . Known hypersensitivity contraindication tacrolimus , corticosteroid 11 . Participation another clinic trial and/or receipt investigational drug within 4 week prior screen 12 . Pregnancy , nursing use nonreliable method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Lupus Nephritis</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Induction Phase</keyword>
</DOC>